Industry News

AbbVie’s continued commitment to gastroenterology

For more than 20 years, AbbVie has been dedicated to improving care for people living with immune disorders. Our longstanding commitment is underscored by our pursuit of cutting-edge science to improve our understanding of complex inflammatory disorders and to ultimately help patients better manage their disease. By innovating, learning and adapting, AbbVie aspires to reduce …

AbbVie’s continued commitment to gastroenterology Read More »

Tillotts LOGIC

Tillotts LOGIC is a training, education and support initiative, developed especially for gastrointestinal healthcare professionals, to improve patient care.
This award-winning IBD education programme includes fully funded weekend modules, an annual education and recognition event and online learning resources available on the NEW Tillotts LOGIC website!
This programme of educational resources is organised and funded by Tillotts Pharma UK, as part of our commitment to reinvest in the NHS.

We are Galapagos UK: The unknown is our comfort zone.

Who we are We are Galapagos, a pioneering biotechnology company, founded in Belgium in 1999 by our CEO Onno van de Stolpe, focused on discovering and developing innovative medicines to improve peoples’ lives. We have over 1000 employees in 10 international locations including the UK, Belgium, Netherlands, France, Germany, Italy and Spain. The UK operation …

We are Galapagos UK: The unknown is our comfort zone. Read More »

Have you registered for the “IBD Clinical Virtual Roadmap 2021”?

Celltrion Healthcare UK Ltd. is supporting a scientific initiative IBD Clinical Virtual Roadmap 2021 for clinicians in IBD. The IBD Clinical Roadmap is a monthly released webinar, available on demand, chaired by Dr Fraser Cummings (Consultant Gastroenterologist Southampton Hospital) and Pearl Avery (IBD Nurse at Dorset County Hospital) where each month an expert guest speaker …

Have you registered for the “IBD Clinical Virtual Roadmap 2021”? Read More »

Olympus Continuum

COVID-19 has had a significant impact on Medical training worldwide with reduced access to face to face training and the need for more flexible solutions. Olympus Continuum is a comprehensive platform of educational programmes and training experiences designed to help you broaden your clinical expertise and enhance your procedural skills – so you can perform …

Olympus Continuum Read More »

Novel treatment option Remsima® SC (infliximab) for Crohn’s disease (CD) and Ulcerative Colitis (UC)

Dr Roisin Bevan, Consultant Gastroenterologist and Leung Yu Wu, Directorate Pharmacist discuss the North Tees and Hartlepool NHS Foundation Trust’s experience of switching to Remsima® SC, the benefits and insights gained. The switching in practice, North Tees and Hartlepool NHS Foundation Trust case study covers multiple aspects of the transition process including: Treatment pathways Choosing …

Novel treatment option Remsima® SC (infliximab) for Crohn’s disease (CD) and Ulcerative Colitis (UC) Read More »

Scroll to Top